drugset
drugset / Trial / NCT04878471

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ASP5354 in Healthy Adult Japanese Male Participants

NCT04878471 ↗

Phase 1 Completed 12 enrolled Astellas Pharma Inc
RandomizedSequentialDouble-blindBasic science

Summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of single intravenous doses of ASP5354 in healthy, adult Japanese male participants.

Timeline

Start
2021-06-02
Primary completion
2021-07-22
Completion
2021-07-22

Drugs

EvaluationDrugModalityDoseRoute
Subject pudexacianinium Diagnostic / imaging agent — Intravenous

Indications

No indication recorded.